Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II

Journal of Vascular Research

Volumn 44, Issue 5, 2007, Pages 391-402

  Chen, Mei Fang ^a   Xie, Xiu Mei ^a   Yang, Tian Lun ^a   Wang, Yong Jin ^c   Zhang, Xiao Hong ^b   Luo, Bai Lin ^a   Li, Yuan Jian ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CHANGZHI MEDICAL COLLEGE   (China)

Author keywords

Angiotensin II; Asymmetric dimethylarginine; CXCR2; Dimethylarginine dimethylaminohydrolase; Interleukin 8; Losartan; Nuclear factor B; Protein arginine methyltransferase

Indexed keywords

ANGIOTENSIN II; ARGININE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR2; DIMETHYLARGININASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LOSARTAN; MESSENGER RNA; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRITE; PROTEIN ARGININE METHYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

AMIDOHYDROLASES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARGININE; CELL ADHESION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-8; LOSARTAN; MONOCYTES; NF-KAPPA B; NITRATES; NITRIC OXIDE; NITRITES; PROTEIN-ARGININE N-METHYLTRANSFERASE; REACTIVE OXYGEN SPECIES; RECEPTORS, INTERLEUKIN-8B; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS; VASCULITIS; VASODILATION;

EID: 34548148963     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103284     Document Type: Article

References (42)

1. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, Roerick O, Gabler C, Strasser R, Daniel WG, Garlichs CD: ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-κB activity and AT1 receptor expression. Biochem Biophys Res Commun 2004;325:532-540.
2. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-711.
3. Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM;RENAAL Investigators: Losartan and end-organ protection - lessons from the RENAAL study. Clin Cardiol 2005;28:136-142.
4. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S, HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005;112:1339-1346.
5. Murphy PM: Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol 1997;34:311-318.
6. Boisvert WA, Curtiss LK, Terkeltaub RA: Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000;21:129-137.
7. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP: An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000;36:2287-2295.
8. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS: Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 2004;287:H782-H790.
9. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148:e5.
10. Delles C, Schneider MP, John S, Gekle M, Schmieder RE: Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G),N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002;15:590-593.
11. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A: Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001;65:775-778.
12. Feng Q, Lu X, Jones DL, Shen J, Arnold JM: Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001;104:700-704.
13. Chen BM, Xia LW, Zhao RQ: Determination of NG, NG-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;692:467-471.
14. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987-992.
15. Lei ZB, Zhang Z, Jing Q, Qin YW, Pei G, Cao BZ, Li XY: Ox-LDL upregulates CXCR 2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc Res 2003;53:524-532.
16. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-658.
17. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I: Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003;166:279-284.
18. Paiva H, Laakso J, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R: Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003;41:219-222.
19. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, Okumura K: High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 2003;18:177-182.
20. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, Bryant TA, Chen NT, Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ: Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000;20:2039-2044.
21. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR: Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:1557-1564.
22. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-1146.
23. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC: Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:1912-1919.
24. Siroen MP, van Leeuwen PA, Nijveldt RJ, Teerlink T, Wouters PJ, Van den Berghe G: Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med 2005;33:504-510.
25. Boger RH: The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003;59:824-833.
26. Boger RH, Sydow K, Borlak J, et al: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99-105.
27. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095.
28. Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, Handelman GJ, Barbato D, Weitzel W, D'Alecy LG, Rajagopalan S: Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant 2003;18:2415-2420.
29. Jiang JL, Li NS, Li YJ, Deng HW: Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002;135:1175-1182.
30. Jiang DJ, Jiang JL, Tan GS, Du YH, Xu KP, Li YJ: Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Naunyn Schmiedebergs Arch Pharmacol 2003;367:600-606.
31. Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T: Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res 2005;320:437-445.
32. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, Morris EM, Szary N, Manrique C, Stump CS: Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006;281:35137-35146.
33. Brasier AR, Recinos A III, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-1266.
34. Xiong Y, Li YJ, Deng HW: Protection of Larginine against oxygen free radicals-injured rabbit aortic endothelium. Zhongguo Yao Li Xue Bao 1994;15:119-123.
35. Jiang DJ, Jia SJ, Dai Z, Li YJ: Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells. J Mol Cell Cardiol 2006;40:529-539.
36. Zernecke A, Weber KS, Erwig LP, Kluth DC, Schroppel B, Rees AJ, Weber C: Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol 2001;166:5755-5762.
37. Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL, Li YJ: Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-κB activity. Naunyn Schmiedebergs Arch Pharmacol 2005;371:401-407.
38. Nabah YN, Mateo T, Estelles R, Mata M, Zagorski J, Sarau H, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ: Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 2004;110:3581-3586.
39. Graninger M, Reiter R, Drucker C, Minar E, Jilma B: Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004;44:335-339.
40. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, Keidar S: The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E-deficient mice. Cardiovasc Res 1999;44:579-587.
41. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM: Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998;83:952-959.
42. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N: Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004;24:1682-1688.